Overview
CJC-1295, also known as Modified GRF 1-29 (Mod GRF 1-29), is a synthetic peptide engineered to mimic growth hormone-releasing hormone (GHRH). Unlike the natural hormone, which has a half-life measured in minutes, CJC-1295 was designed with Drug Affinity Complex (DAC) technology to extend its circulating lifespan to 6-8 days. This extended duration allows for sustained stimulation of the body's natural growth hormone production with infrequent dosing—typically once weekly.
The compound operates in research and performance contexts as a growth hormone secretagogue, meaning it prompts the body to release more of its own growth hormone rather than delivering synthetic hormone directly. This mechanism distinguishes it from exogenous hormone replacement and makes it appealing to individuals interested in optimizing endogenous hormone production.
CJC-1295 is administered via injection and is frequently stacked with other peptides—most commonly GHRPs (growth hormone-releasing peptides) like ipamorelin—to create synergistic effects on growth hormone secretion. However, it is important to note upfront that CJC-1295 is not approved by the FDA for human use and remains primarily a research compound.
How CJC-1295 Works: Mechanism of Action
The GHRH Receptor Pathway
CJC-1295 functions by binding to and activating GHRH receptors (GHRHR) located on somatotroph cells in the anterior pituitary gland. Somatotrophs are the specialized cells responsible for synthesizing and releasing growth hormone. When CJC-1295 activates these receptors, it triggers the pituitary to increase the synthesis and pulsatile (wave-like) secretion of endogenous growth hormone.
This represents a key distinction from direct hormone injection: CJC-1295 works with the body's natural signaling cascade rather than bypassing it. The peptide essentially amplifies an existing biological signal.
The DAC Technology and Extended Half-Life
The critical innovation behind CJC-1295 is its DAC (Drug Affinity Complex) modification. This chemical modification enables CJC-1295 to covalently bind to serum albumin—the most abundant protein in blood plasma—via a maleimide-lysine linkage. This binding dramatically extends the peptide's half-life from the 2-3 minute half-life of native GHRH to 5.8-8.1 days in humans.
Because the peptide remains bound to albumin and circulates continuously in the bloodstream, it can sustain receptor stimulation over an extended period, permitting once-weekly dosing schedules rather than multiple daily injections.
Downstream Effects: GH and IGF-1 Elevation
Elevated growth hormone levels subsequently trigger the liver to increase production of insulin-like growth factor 1 (IGF-1), a critical mediator of growth hormone's anabolic, lipolytic (fat-burning), and tissue-repair effects. This IGF-1 elevation underlies many of the theoretical benefits attributed to CJC-1295, including muscle growth, fat loss, and recovery enhancement.
Evidence by Health Goal
Muscle Growth
Evidence Tier: 2 (Limited Human Data)
CJC-1295 reliably increases both GH and IGF-1 levels in humans, but clinical evidence directly measuring muscle growth, strength gains, or body composition changes does not yet exist.
In a human randomized controlled trial, a single injection of CJC-1295 produced dose-dependent increases in mean plasma growth hormone of 2- to 10-fold, sustained for 6 or more days. The same injection elevated IGF-1 levels by 1.5- to 3-fold for 9-11 days following administration. With repeated dosing, IGF-1 remained above baseline for up to 28 days.
While these hormonal changes align theoretically with conditions favorable to muscle protein synthesis, no clinical trial has directly measured lean muscle accrual, strength improvements, or changes in body composition in humans receiving CJC-1295. Therefore, efficacy for muscle growth in humans remains unproven despite mechanistic plausibility.
Fat Loss
Evidence Tier: 1 (No Rigorous Human Evidence)
No clinical evidence demonstrates that CJC-1295 reduces body fat in humans. The available literature consists of a netnographic review of online forum discussions and one animal study in GHRH knockout mice.
The netnography identified 23 discussion threads in which female forum users reported choosing CJC-1295 for weight loss, muscle enhancement, and youthful skin. However, this study captured qualitative, anecdotal self-reports without measured clinical outcomes.
In GHRH knockout mice receiving once-daily CJC-1295 (2 μg per 24 hours) over 5 weeks, the peptide normalized body weight and length compared to placebo-treated knockout mice. Notably, relative lean mass and subcutaneous fat mass were normal in all treated groups—indicating restoration to normal phenotype rather than fat loss relative to control animals.
Human fat loss efficacy remains undemonstrated.
Injury Recovery
Evidence Tier: 1 (Theoretical Only, No Clinical Trial Data)
CJC-1295 is mentioned in review articles as a growth hormone secretagogue with theoretical potential to activate IGF-1 signaling relevant to muscle repair and tissue regeneration. However, no clinical or animal trial data specific to injury recovery outcomes have been published.
Reviews explicitly acknowledge the current lack of clinical trials evaluating peptides in orthopaedic injury contexts. While the mechanistic rationale—that elevated IGF-1 may promote satellite cell activation and muscle protein synthesis—is sound, clinical validation is absent.
Anti-Inflammation
Evidence Tier: 1 (Theoretical Only)
CJC-1295 is classified in reviews as a growth hormone-releasing hormone analogue with theoretical anti-inflammatory potential through IGF-1 signaling and tissue regeneration pathways. However, no human or animal studies specifically demonstrating efficacy for inflammation outcomes have been published.
Cognition
Evidence Tier: 1 (No Studies)
CJC-1295 has not been studied for cognitive, memory, or brain function effects in any available literature. Available publications focus exclusively on growth hormone secretion, physical growth, and pituitary function.
Sleep
Evidence Tier: 1 (No Studies)
CJC-1295 is not studied or discussed in relation to sleep outcomes in the available literature. While it is mentioned as a growth hormone secretagogue in one orthopaedic review, no sleep-specific data or research exists.
Longevity
Evidence Tier: 1 (No Human Studies)
CJC-1295 has not been studied for longevity or lifespan extension in humans. The only available evidence is a single animal study in GHRH-deficient mice showing normalized growth parameters—a finding that does not address aging or lifespan.
Skin & Hair
Evidence Tier: 1 (No Rigorous Evidence)
No rigorous human evidence demonstrates that CJC-1295 improves skin or hair health. Online forum users reported interest in the peptide for "youthful skin," but no objective skin assessments were performed in any clinical study.
One mechanistic study measured serum protein profile changes in 11 healthy men receiving CJC-1295 injection, noting decreased apolipoprotein A1 and transthyretin isoforms alongside increased beta-hemoglobin and albumin fragments. This biomarker study did not include any direct skin or hair measurements.
Heart Health
Evidence Tier: 1 (No Clinical Studies)
CJC-1295 has not been studied for cardiovascular health or efficacy in any available clinical literature. Available abstracts address doping detection and sports misuse without clinical safety or efficacy data.
However, emerging reviews suggest that peptide therapies used at supraphysiological doses may carry potential cardiovascular risks including cardiovascular strain, insulin resistance, and dyslipidemia. These concerns remain theoretical without CJC-1295-specific clinical data.
Hormonal Balance
Evidence Tier: 3 (Demonstrated in Controlled Settings, Limited Trials)
CJC-1295 consistently increases growth hormone and IGF-1 levels in humans with a long-acting profile (half-life 5.8-8.1 days). A single injection produced dose-dependent GH increases of 2- to 10-fold sustained for 6 or more days, with IGF-1 elevations of 1.5- to 3-fold persisting for 9-11 days.
Evidence is limited to two small randomized controlled trials. While hormonal elevation is reliably demonstrated, the clinical significance of these changes for health outcomes beyond hormone elevation remains unproven.
Athletic Performance
Evidence Tier: 1 (No Controlled Trials)
No rigorous human evidence exists for CJC-1295's effects on athletic performance, strength, speed, or endurance. Available data consist only of narrative reviews discussing anecdotal online forum reports with no controlled trials, objective measurements, or clinical validation.